X

    Xenon Pharmaceuticals Inc (XENE)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $60.22
    +0.23 (+0.38%)

    Market Cap: $5.81B

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    50%(20/40)
    Avg Surprise
    -5.99%
    Streak
    2 Q

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-1.16
    Range$-1.29 - $-0.94
    14 analysts
    EPS Revisions
    3
    0
    7d
    3
    2
    30d
    EPS Estimate Drift
    90d ago$-1.19-3.1%
    60d ago$-1.19-3.1%
    30d ago$-1.19-3.1%
    7d ago$-1.19-3.1%
    Current$-1.16
    Revenue Consensus
    $0
    Range$0 - $0
    16 analysts
    Dec 31, 2026
    EPS Consensus$-1.12
    Range$-1.41 - $-0.54
    14 analysts
    Revenue Consensus
    $-754320
    Range$-1937500 - $6M
    17 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-1.12---
    Sep 26EST
    		-$-1.16---
    Jun 26
    		$-1.11$-1.16+4.31%Beat-3.7%
    Mar 26
    		$-1.17$-1.20+2.50%Beat-41.0%
    Dec 25
    		$-1.31$-1.20-9.17%Miss-56.0%
    Sep 25
    		$-1.15$-1.16+0.86%Beat-42.0%
    Jun 25
    		$-1.07$-0.99-8.08%Miss-42.7%
    Mar 25
    		$-0.83$-0.90+7.78%Beat-33.9%
    Dec 24
    		$-0.84$-0.84-0.10%Miss-31.2%
    Sep 24
    		$-0.81$-0.79-2.53%Miss-11.0%
    Jun 24
    		$-0.75$-0.68-10.29%Miss-4.2%
    Mar 24
    		$-0.62$-0.65+4.62%Beat+1.6%
    Dec 23
    		$-0.64$-0.76+15.79%Beat-12.3%
    Sep 23
    		$-0.73$-0.75+2.67%Beat-28.1%
    Jun 23
    		$-0.72$-0.67-7.46%Miss-30.9%
    Mar 23
    		$-0.63$-0.60-5.00%Miss-80.0%
    Dec 22
    		$-0.57$-0.58+1.72%Beat-18.7%
    Sep 22
    		$-0.57$-0.53-7.55%Miss-58.3%
    Jun 22
    		$-0.55$-0.50-10.00%Miss-7.8%
    Mar 22
    		$-0.35$-0.41+14.63%Beat+16.7%
    Dec 21
    		$-0.48$-0.37-29.73%Miss-41.2%
    Sep 21
    		$-0.36$-0.44+18.18%Beat-44.0%
    Jun 21
    		$-0.51$-0.49-4.08%Miss-10308.2%
    Mar 21
    		$-0.42$-0.39-7.69%Miss-90.9%
    Dec 20
    		$-0.34$-0.40+15.00%Beat+19.0%
    Sep 20
    		$-0.25$-0.17-47.06%Miss+24.2%
    Jun 20
    		$-0.00N/A+97.55%Beat+98.7%
    Mar 20
    		$-0.22$-0.31+29.03%Beat+47.6%
    Dec 19
    		$-0.42$-0.48+12.50%Beat-44.8%
    Sep 19
    		$-0.33$-0.46+28.26%Beat+47.6%
    Jun 19
    		$-0.37$-0.45+17.78%Beat+17.8%
    Mar 19
    		$-0.42$-0.37-13.51%Miss+8.7%
    Dec 18
    		$-0.29$-0.37+21.62%Beat+35.6%
    Sep 18
    		$-0.63$-0.40-57.50%Miss-46.5%
    Jun 18
    		$-0.45$-0.49+8.16%Beat-9.8%
    Mar 18
    		$-0.46$-0.48+4.17%Beat-9.5%
    Dec 17
    		$-0.45$-0.11-309.09%Miss-40.6%
    Sep 17
    		$-0.43$-0.39-10.26%Miss+15.7%
    Jun 17
    		$-0.41$-0.39-5.13%Miss-
    Mar 17
    		$-0.42$-0.38-10.53%Miss-
    Dec 16
    		$-0.32$-0.42+23.81%Beat-
    Sep 16
    		$-0.51$-0.44-15.91%Miss-

    Key Metrics

    Valuation
    P/E Ratio-12.70EV/EBITDA34.16x
    Price/FCF-17.72xFCF Yield-5.64%
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-43.60%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio21.02xQuick Ratio21.02x
    Trading Statistics
    Beta0.63Avg Volume675.18K
    52-Week High$72.6652-Week Low$35.60

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$61.29
    SMA 20$62.54
    SMA 50$63.17
    SMA 200$52.39
    EMA 10$61.41
    EMA 20$62.14
    EMA 50$61.71
    EMA 200$53.83

    MACD

    Line: -0.71Signal: -0.43Hist: -0.28

    ADX

    ADX: 14.9+DI: 21.6-DI: 22.7

    Aroon & PSAR

    Aroon Up4.0
    Aroon Down100.0
    PSAR$64.81

    Bollinger Bands

    Upper Band$66.01
    Lower Band$59.06
    %B Position1111%(Upper)
    Band Width0.17

    RSI (14-Day)

    Neutral
    43.2

    Momentum Oscillators

    Stoch %K22.7
    Stoch %D35.7
    Williams %R-84.6
    ROC (10d)-3.4%
    Momentum-2.14
    CCI (20d)-128.1
    MFI (14d)47.7

    Volatility Measures

    ATR (14d)$2.26(3.8%)
    StdDev (20d)1.74
    Hist Vol38.3%(Moderate)

    Volume Flow

    VWAP$60.08
    OBV23.3M
    AD Line-2.1M
    CMF (20d)-0.033

    Volume Metrics

    Avg Vol (20d)681.9K
    Vol Ratio1.1x
    VWMA (20d)$62.59

    Pivot Points

    R3$62.95
    R2$62.28
    R1$61.14
    Pivot Point$60.47
    S1$59.33
    S2$58.66
    S3$57.52

    Advanced Oscillators

    TSI-8.94
    Ultimate Osc47.1
    KST-45.56

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$7.50M$2.52M$0$0$0$5.38M$0
    Cost of Revenue$0$0$611,000$0$0$0$633,000$0$0$0$851,000$0
    Gross Profit$0$0$-611,000$0$0$7.50M$1.26M$0$0$0$4.53M$0
    Operating Expenses$123.16M$112.33M$109.77M$96.34M$94.23M$80.24M$77.48M$73.68M$69.10M$59.04M$53.70M$55.68M
    R&D$99.22M$88.51M$87.70M$77.05M$74.98M$61.20M$59.47M$56.97M$49.70M$44.25M$41.08M$42.88M
    SG&A$23.93M$23.82M$22.07M$19.28M$19.24M$19.04M$18.00M$16.71M$19.40M$14.79M$12.62M$12.80M
    Operating Income$-123,155,000$-112,328,000$-109,767,000$-96,336,000$-94,229,000$-72,738,000$-77,477,000$-73,676,000$-69,104,000$-59,041,000$-53,695,000$-55,684,000
    Interest Income$12.14M$6.91M$5.34M$6.21M$7.20M$8.08M$9.42M$10.33M$10.84M$11.36M$8.69M$6.98M
    Interest Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$-111,321,000$-104,873,000$-104,723,000$-90,219,000$-85,332,000$-64,620,000$-69,533,000$-63,110,000$-58,257,000$-47,519,000$-44,948,000$-48,619,000
    Income Tax Expense$-585,000$-2,571,000$538,000$677,000$-626,000$427,000$-3,848,000$-320,000$-333,000$412,000$-205,000$-157,000
    Net Income$-110,736,000$-102,302,000$-105,261,000$-90,896,000$-84,706,000$-65,047,000$-65,685,000$-62,790,000$-57,924,000$-47,931,000$-44,743,000$-48,462,000
    EBITDA$-122,908,000$-111,193,000$-109,452,000$-95,784,000$-91,899,000$-72,044,000$-78,289,000$-72,772,000$-68,453,000$-58,288,000$-54,268,000$-53,867,000
    EBIT$-123,466,000$-111,780,000$-110,063,000$-96,425,000$-92,531,000$-72,703,000$-78,955,000$-73,439,000$-69,094,000$-58,874,000$-53,639,000$-55,601,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about XENE

    News

    Bank of America Corp DE Increases Stock Holdings in Xenon Pharmaceuticals Inc. $XENE

    Bank of America Corp DE has increased its stock holdings in Xenon Pharmaceuticals Inc. by 19.8% during the first quarter, now owning 265,267 shares valued at $15.42 million. Other institutional investors have also adjusted their positions in XENE, with hedge funds and institutional investors collectively owning 95.45% of the stock. Despite a recent trading dip, analysts maintain a "Buy" consensus rating for Xenon Pharmaceuticals, with an average target price of $77.13.

    MarketBeat•8/21/26•
    Neutral

    Should Xenon’s Wider Q2 Losses to Fund Neurology Pipeline Require Action From Xenon (XENE) Investors?

    Xenon Pharmaceuticals Inc. reported wider Q2 2026 losses, with a net loss of US$110.74 million, as it invests heavily in its ion-channel neurology pipeline. The increased losses highlight the company's funding needs and the potential for dilution as it moves towards commercializing its lead epilepsy drug, azetukalner, and building out its commercial infrastructure. Investors are advised to consider how these rising costs impact the company's investment narrative, particularly with upcoming milestones like the planned U.S. NDA submission for azetukalner.

    Simply Wall Street•8/19/26•
    Somewhat-Bearish

    Should Xenon’s Wider Q2 Losses to Fund Neurology Pipeline Require Action From Xenon (XENE) Investors?

    Xenon Pharmaceuticals recently reported wider Q2 2026 losses, reaching US$110.74 million, as it funds its ion-channel neurology pipeline, particularly ahead of the planned U.S. NDA submission for azetukalner. These rising losses bring funding needs and potential dilution into focus, prompting investors to assess the company's transition from an R&D focus to an early commercial stage. Despite these challenges, analysts project significant revenue growth and a fair value suggesting a 28% upside.

    Simply Wall Street•8/19/26•
    Somewhat-Bearish

    Should Xenon’s Wider Q2 Losses to Fund Neurology Pipeline Require Action From Xenon (XENE) Investors?

    Xenon Pharmaceuticals Inc. (XENE) reported wider Q2 2026 net losses of US$110.74 million, funding its neurology pipeline. The company's investment narrative hinges on azetukalner's success, with upcoming catalysts like a U.S. NDA submission and a presence at Stifel’s 2026 Biotech Summer Summit. While analysts project significant revenue growth and a fair value upside, the increasing losses highlight ongoing funding needs and potential dilution risks for investors.

    Sahm•8/18/26•
    Somewhat-Bearish

    TimesSquare Capital Management LLC Purchases Shares of 451,593 Xenon Pharmaceuticals Inc. $XENE

    TimesSquare Capital Management LLC has acquired 451,593 shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a new position valued at approximately $27.3 million, giving them a 0.47% stake in the biopharmaceutical company. Institutional investors collectively own 95.45% of the stock. Xenon Pharmaceuticals recently reported better-than-expected quarterly adjusted EPS and maintains a "Buy" consensus rating from analysts, despite recent insider share sales.

    MarketBeat•8/18/26•
    Somewhat-Bullish

    Frequently Asked Questions About XENE

    Does XENE pay dividends?
    Xenon Pharmaceuticals Inc (XENE) does not currently pay a regular dividend.
    What is XENE's market cap?
    Xenon Pharmaceuticals Inc (XENE) has a market capitalization of $5.81B with a current stock price of $60.22.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In